Permeability of the mouse blood-brain barrier to murine interleukin-2: Predominance of a saturable efflux system

Brain, Behavior, and Immunity

Volumn 18, Issue 5, 2004, Pages 434-442

  Banks, William A ^a   Niehoff, Michael L ^a   Zalcman, Steven S ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM; CIRCULATION; CONTROLLED STUDY; ISOTOPE LABELING; KINETICS; MALE; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2; MALE; MICE; RANDOM ALLOCATION; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 3242694170     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2003.09.013     Document Type: Article

References (64)

1. Alonso R., Chaudieu I., Diorio J., Krishnamurthy A., Quirion R., Boksa P. Interleukin-2 modulates evoked release of [3H]dopamine in a rat cultured mesencephalic cells. J. Neurochem. 61:1993;1284-1290
2. Anisman H., Kokkinidis L., Merali Z. Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Res. 731:1996;1-11
3. Awatsuji D.M., Furukawa Y., Nakajima M., Furukawa K., Hayashi K. Interleukin-2 as a neurotrophic factor for supporting the survival of neurons cultured from various regions of fetal rat brain. J. Neurosci. Res. 35:1993;305-311
4. Banks W.A., Broadwell R.D. Blood to brain and brain to blood passage of native horseradish peroxidase, wheat germ agglutinin and albumin: pharmacokinetic and morphological assessments. J. Neurochem. 62:1994;2404-2419
5. Banks W.A., Farr S.A., La Scola M.E., Morley J.E. Intravenous human interleukin-1α impairs memory processing in mice: dependence on blood-brain barrier transport into posterior division of the septum. J. Pharmacol. Exp. Ther. 299:2001;536-541
6. Banks W.A., Kastin A.J. Quantifying carrier-mediated transport of peptides from the brain to the blood. Conn P.M. Methods in Enzymology. vol. 168:1989;652-660 Academic Press, San Diego
7. Banks W.A., Kastin A.J. Regulation of the passage of peptides across the blood-brain barrier. Garzone P.D., Colburn W.A., Mokotoff M. Pharmacokinetics and Pharmacodynamics. Peptides, Peptoids and Proteins. vol. 3:1991;147-153 Harvey Whitney Books, Cincinnati, OH
8. Banks, W.A., Kastin, A.J., 1993. Peptide binding in blood and passage across the blood-brain barrier. In: Tillement, J.P., Eckert, H., Albengres, E., Barre, J., Baumann, P., Belpare, F., Lemaire, M. (Eds.), Proceedings of the International Symposium on Blood Binding and Drug Transfer, Fort and Clair, Paris, pp. 223-242
9. Banks W.A., Kastin A.J., Durham D.A. Bidirectional transport of interleukin-1 alpha across the blood-brain barrier. Brain Res. Bull. 23:1989;433-437
10. Banks W.A., Kastin A.J., Fischman A.J., Coy D.H., Strauss S.L. Carrier-mediated transport of enkephalins and N-Tyr-MIF-1 across blood-brain barrier. Am. J. Physiol. 251:1986;E477-E482
11. Banks W.A., Kastin A.J., Gutierrez E.G. Penetration of interleukin-6 across the blood-brain barrier. Neurosci. Lett. 179:1994;53-56
12. Banks W.A., Ortiz L., Plotkin S.R., Kastin A.J. Human interleukin (IL) 1α, murine IL-1α and murine IL-1β are transported from blood to brain in the mouse by a shared saturable mechanism. J. Pharmacol. Exp. Ther. 259:1991;988-996
13. Banks W.A., Plotkin S.R., Kastin A.J. Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation. 2:1995;161-165
14. Baranczyk-Kuzma A., Audus K.L. Characteristics of aminopeptidase activity from bovine brain microvessel endothelium. J. Cereb. Blood Flow Metab. 7:1987;801-805
15. Bartholomew S.A., Hoffman S.A. Effects of peripheral cytokine injections on multiple unit activity in the anterior hypothalamic area of the mouse. Brain Behav. Immunity. 7:1993;301-316
16. Begley D.J. The interaction of some centrally active drugs with the blood-brain barrier and circumventricular organs. Prog. Brain Res. 91:1992;163-169
17. Blasberg R.G., Fenstermacher J.D., Patlak C.S. Transport of α-aminoisobutyric acid across brain capillary and cellular membranes. J.Cereb. Blood Flow Metab. 3:1983;8-32
18. Bodnar R.J., Pasternak G.W., Mann P.E., Paul D., Warren R., Donner D.B. Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Cancer Res. 15:1989;6280-6284
19. Brownson E.A., Abbruscato T.J., Gillespie T.J., Hruby V.J., Davis T.P. Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J. Pharmacol. Exp. Ther. 270:1994;675-680
20. Caraceni A., Martini C., Belli F., Mascheroni L., Rivoltini L., Arienti F., Casinelli N. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur. J. Cancer. 29A:1992;1266-1269
21. Cashion M.F., Banks W.A., Kastin A.J. Sequestration of centrally administered insulin by the brain: effects of starvation, aluminum, and TNF-α Hormone Behav. 30:1996;280-286
22. 125I-labelled interleukin-6 from brain into blood following intracerebroventricular injection in rats. Endocrinology. 138:1997;4830-4836
23. 125I]-tumor necrosis factor-α from the brain into the blood after intracerebroventricular injection into rats. Neuroimmunomodulation. 5:1998;261-269
24. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 295:2002;2264
25. Denicoff K.D., Rubinow D.R., Papa M.Z., Simpson C., Seipp C.A., Lotze M.T., Chang A.E., Rosenstein D., Rosenberg S.A. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 107:1987;293-300
26. Drach J., Gsur A., Hamilton G., Zhao S., Angerler J., Fiegl M., Zojer N., Raderer M., Haberl I., Andreeff M., Huber H. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood. 88:1996;1747-1754
27. Elferink R.P.J.O., Zadina J.E. MDR1 P-glycoprotein transports endogenous opioid peptides. Peptides. 22:2001;2015-2020
28. Fent K., Zbinden G. Toxicity of interferon and interleukin. Trends Pharmacol. Sci. 8:1987;100-105
29. Ghersi-Egea J.F., Gorevic P.D., Ghiso J., Frangione B., Patlak C.S., Fenstermacher J.D. Fate of cerebrospinal fluid-borne amyloid β-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67:1996;880-883
30. Gutierrez E.G., Banks W.A., Kastin A.J. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 47:1993;169-176
31. Habif D.V., Lipton R., Cantell K. Interferon crosses the blood-cerebrospinal fluid barrier in monkeys. Proc. Soc. Exp. Biol. Med. 149:1975;287-289
32. Hanisch U.-K., Neuhaus J., Rowe W., van Rossum D., Moller T., Kettenmann H., Quirion R. Neurotoxic consequences of central long-term administration of interleukin-2 in rats. Neuroscience. 79:1997;799-818
33. Hardebo J.E., Owman C. Enzymatic barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain barrier. Johansson B.B., Owman C., Widner H. Pathophysiology of the Blood-Brain Barrier. 1990;41-55 Elsevier, Amsterdam
34. Lacosta S., Merali Z., Anisman H. Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety. Behav. Neurosci. 113:1999;1030-1041
35. Lacosta S., Merali Z., Anisman H. Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation. 8:2000;83-90
36. Lapchak P.A. A role for interleukin-2 in the regulation of striatal dopaminergic function. Neuroreport. 3:1992;165-168
37. Licinio J., Seibyl J.P., Altemus M., Charney D.S., Krystal J.H. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiat. 150:1993;1408-1410
38. List J., Moser R.P., Steuer M., Loudon W.G., Blacklock J.B., Grimm E.A. Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1beta, gamma interferon, and soluble interleukin 2 receptor (M 55,000 protein). Cancer Res. 52:1992;1123-1128
39. Maness L.M., Kastin A.J., Farrell C.L., Banks W.A. Fate of leptin after intracerebroventricular injection into the mouse brain. Endocrinology. 139:1998;4556-4562
40. McCallister C.G., Van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M., Yao J., Peters J.L. Increases in CSF levels of interleukin 2: effects of recurrence of psychosis and medication status. Am. J. Psychiat. 152:1995;1291-1297
41. Meyers C.A. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv. Exp. Med. Biol. 461:1999;75-81
42. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3:1983;1-7
43. Pauli S., Linthorst A.C., Reul J.M. Tumour necrosis factor-alpha and interleukin-2 differentially affect hippocampal serotonergic neurotransmission, behaviournal activity, body temperature and hypothalamic-pituitary- adrenocortical axis activity in the rat. Eur. J. Neurosci. 10:1998;868-878
44. Petitto J.M., McCarthy D.B., Rinker C.M., Huang Z., Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. Neuroimmunomodulation. 73:1997;183-190
45. Plotkin S.R., Banks W.A., Maness L.M., Kastin A.J. Differential transport of rat and human interleukin-1α across the blood-brain barrier and blood-testis barrier in rats. Brain Res. 881:2000;57-61
46. Pretorius H.T., Kastin A.J., Banks W.A. Binding of Tyr-MIF-1 to isolated brain capillaries. Brain Res. Bull. 17:1986;829-831
47. Raber J., Koob G.F., Bloom F.E. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling mechanism: comparison with the hypothalamic response. J. Pharmacol. Exp. Ther. 272:1995;815-824
48. Rapapport M.H., Caliguiri M.P., Lohr J.B. An association between increased soluble interleukin-2 receptors and a disturbance in motor muscle force in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatr. 21:1997;817-827
49. Rapapport M.H., Lohr J.B. Serum soluble interleukin-2 receptors in neuroleptic naive schizophrenic patients and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand. 90:1994;311-315
50. Romero L.I., Kakucska I., Lechan R.M., Reichlin S. Interleukin-6 (IL-6) is secreted from the brain after intracerebroventricular injection of IL-1β in rats. Am. J. Physiol. 270:1996;R518-R524
51. Sarder M., Saito H., Abe K. Interleukin-2 promotes survival and neurite extension of cultured neurons from fetal rat brain. Brain Res. 625:1993;347-350
52. Shayo M., McLay R.N., Kastin A.J., Banks W.A. The putative blood-brain barrier transporter for the β-amyloid binding protein apolipoprotein J is saturated at physiological concentrations. Life Sci. 60:1996;L115-L118
53. Smith Q.R., Momma S., Aoyagi M., Rapoport S.I. Kinetics of neutral amino acid transport across the blood-brain barrier. J. Neurochem. 49:1987;1651-1658
54. Song C., Merali Z., Anisman H. Variations of nucleus accumbens dopamine or serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neurosci. 88:1999;823-836
55. Triguero D., Buciak J., Pardridge W.M. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54:1990;1882-1888
56. Waguespack P.J., Banks W.A., Kastin A.J. Interleukin-2 does not cross the blood-brain barrier by a saturable transport system. Brain Res. Bull. 34:1994;103-109
57. West W.H., Tauer K.W., Yannelli J.R., Marshall G.D., Orr D.W., Thurman G.B., Oldham R.K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316:1987;898-905
58. Ye J.H., Tao L., Zalcman S.S. Interleukin-2 modulates N-methyl-D-aspartate receptors of native mesolimbic neurons. Brain Res. 894:2001;241-248
59. Zalcman S., Green-Johnson J.M., Murray L., Dyck D.G., Nance D.M., Anisman H., Greenberg A.H. Cytokine-specific central monoamine alterations induced by interleukin-1, -2, and -6. Brain Res. 643:1994;40-49
60. Zalcman S., Green-Johnson J.M., Murray L., Wan W., Nance D.M., Greenberg A.H. Interleukin-2 induced enhancement of an antigen-specific IgM PFC response is mediated by the sympathetic nervous system. J. Pharmacol. Exp. Ther. 271:1994;977-982
61. Zalcman S., Murray L., Dyck D.G., Greenberg A.H., Nance D.M. Interleukin-2 and -6 induce behavioral-activating effects in mice. Brain Res. 811:1998;111-121
62. Zalcman S.S. Interleukin-2 potentiates novelty - and GBR 12909-induced exploratory activity. Brain Res. 899:2001;1-9
63. Zalcman S.S. Interleukin-2-induced increases in climbing behavior: inhibition by dopamine D-1 and D-2 receptor antagonists. Brain Res. 944:2002;157-164
64. Zlokovic B.V., Lipovac M.N., Begley D.J., Davson H., Rakic L. Slow penetration of thyrotropin-releasing hormone across the blood-brain barrier of an in situ perfused guinea pig brain. J. Neurochem. 51:1988;252-257